Bausch + Lomb saw its stock surge by 13% in Toronto, trading at 24.01 Canadian dollars (around $17.67), following a report by the Financial Times suggesting the eye care company is considering a sale. The possible sale is being considered as a way to separate from its heavily indebted parent company, Bausch Health Companies Inc. […]
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA is a non-steroid eye drop specifically designed for treating the signs and symptoms of dry eye disease (DED) with a focus on inflammation associated with this condition, along with acquiring […]
Bausch + Lomb, an esteemed global eye health company, has broadened its portfolio by purchasing Johnson & Johnson Vision’s Blink product line for $106.5 million. The acquisition, financed using existing cash, underscores Bausch + Lomb’s ongoing commitment to enhancing consumer convenience in over-the-counter (OTC) eye care. The Blink range, now under Bausch + Lomb’s umbrella, […]
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast ophthalmic solution) 5%, known for treating dry eye disease (DED) symptoms. The transaction, which includes a $1.75 billion upfront cash payment, will see the global eye health giant adding the lucrative product, which had sales of approximately […]